ADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDY

Abstract

The Zoladex In Pre-menopausal Patients (ZIPP) study was designed to determine whether addition of goserelin (‘Zoladex’) and/or tamoxifen to adjuvant therapy (radiotherapy and/or chemotherapy), provided benefit to pre- or peri-menopausal women with operable, early breast cancer.

Keywords

• ovarian ablation
• goserelin
• adjuvant
• chemotherapy
• early breast cancer
• pre-menopausal